Unitil (NYSE:UTL) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.16 by 8.62 percent. This is a 23.53 percent increase over earnings of $1.02 per share from the same period last year.
Global Blood Therapeutics’s Return On Capital Employed Overview
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter.
